Norrin,Immunoglobulin gamma-1 heavy chain
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Insufficient information Heteromer Protein × 6 PDB declaration: hexameric（6） Consistent with protein copy count | Chain E； UniProt 220–449 Chain F； UniProt 220–449 | Not recorded | MB52 × 2 Leucine-rich repeat-containing G-protein coupled receptor 4 × 2 （Q9BXB1） | ELECTRON MICROSCOPY cryo-EM buffer：pH 7.4 cryo-EM vitrification conditions：Cryogen ETHANE | Resolution 3.65 Å |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 9KHH | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1D5B UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25%PEG 1000, 100mM sodium acetate, 300mM CdCl2, 100mM ammonium sulfate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.285 |
| 1D5B UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25%PEG 1000, 100mM sodium acetate, 300mM CdCl2, 100mM ammonium sulfate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.285 |
| 1D5B UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；25%PEG 1000, 100mM sodium acetate, 300mM CdCl2, 100mM ammonium sulfate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.285 |
| 1D5I UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY Deposited 1999-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；75mM Hepes pH 7.0 9% PEG 4000 150 mM Ammonium Sulfate 20% 1,4 butanediol 100 mM Cadmium Chloride, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.263 |
| 1D6V CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION Deposited 1999-10-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
120–220（101 aa）
Fragment：chimeric fab fragment (UNP K7T9I5 residues 1-112, P0DOX5 residues 120-220)
|
Not recorded | CD CADMIUM ION × 4 HOP (1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；292 K；9% polyethylene glycol 4000 250mM ammonium sulfate 80mM Cadmium Chloride 75mM Hepes 20% 1,4 butanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 19K
|
Resolution 2.00 Å R-free 0.264 |
| 1HZH CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN Deposited 2001-01-24 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
117–449（333 aa）
Chain K
117–449（333 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295.5 K；NH4SO4, cacodylate, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 295.5K
|
Resolution 2.70 Å R-free 0.273 |
| 1N0X Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope Deposited 2002-10-15 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain H
117–222（106 aa）
Fragment：UNP residues 117-222
Chain K
117–222（106 aa）
Fragment：UNP residues 117-222
|
Not recorded | GOL GLYCEROL × 8 SO4 SULFATE ION × 4 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 1 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 10.5；295.5 K；ammonium sulfate, lithium sulfate, CAPS buffer, pH 10.5, VAPOR DIFFUSION, SITTING DROP, temperature 295.5K
|
Resolution 1.80 Å R-free 0.252 |
| 3PGF Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (sAB) Deposited 2010-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
121–227（107 aa）
|
Not recorded | IMD IMIDAZOLE × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；292 K；19% PEG 3400, 8% Tacsimate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 2.10 Å R-free 0.227 |
| 4R26 Crystal structure of human Fab PGT124, a broadly neutralizing and potent HIV-1 neutralizing antibody Deposited 2014-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
115–223（109 aa）
|
Not recorded | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；20% PEG 4000, 0.2M MgCl2, 0.1M Tris-HCL, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.267 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain Q
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain J
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 4R2G Crystal Structure of PGT124 Fab bound to HIV-1 JRCSF gp120 core and to CD4 Deposited 2014-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain N
115–223（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 CL CHLORIDE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；2.4M ammonium sulphate, 0.1M Tris, 13% glycerol, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.28 Å R-free 0.263 |
| 5O4E Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6 Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
Chain C
227–448（222 aa）
Chain D
227–449（223 aa）
|
Mutation：T350V, T366L, K392L, T394W Mutation：;T350V, L351Y, T359R, K360F, N361Y, E388D, N389I, F389a, P389b, N389c, G389d, L389e, F405A, Y407V, D413P, K414Y, S415P, R416S, Q418L, Q419M, N421T, V422R, S440H, S442E, L443Y, S444Q, P445W, G446P, K447T ; Mutation：T350V, T366L, K392L, T394W Mutation：;T350V, L351Y, T359R, K360F, N361Y, E388D, N389I, F389a, P389b, N389c, G389d, L389e, F405A, Y407V, D413P, K414Y, S415P, R416S, Q418L, Q419M, N421T, V422R, S440H, S442E, L443Y, S444Q, P445W, G446P, K447T ; | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 10 MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1 CAC CACODYLATE ION × 2 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；0.1 M Sodium cacodylate,
40% (v/v) MPD,
5% (w/v) PEG 8000
|
Resolution 2.15 Å R-free 0.236 |
| 5VJ6 BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195 Deposited 2017-04-18 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 14 PDB declaration: tetradecameric |
Chain H
117–224（108 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 11.50 Å |
| 5VU0 Crystal structure of the complex between afucosylated/galactosylated human IgG1 Fc and Fc gamma receptor IIIa (CD16A) with Man5 N-glycans Deposited 2017-05-18 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
230–446（217 aa）
Fragment：Fc region (UNP residues 230-446)
Chain B
230–446（217 aa）
Fragment：Fc region (UNP residues 230-446)
|
Not recorded | EDO 1,2-ETHANEDIOL × 5 PEG DI(HYDROXYETHYL)ETHER × 4 NA SODIUM ION × 9 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM Bis-Tris Propane pH 7.5, 16% PEG 20k, 100 mM Potassium thiocyanate, Cryo protection - 20% Ethylene Glycol
|
Resolution 2.26 Å R-free 0.237 |
| 5VZX Crystal structure of crenezumab Fab Deposited 2017-05-29 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
115–227（113 aa）
Chain H
115–227（113 aa）
|
Not recorded | SO4 SULFATE ION × 11 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.4 M ammonium sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.230 |
| 5VZX Crystal structure of crenezumab Fab Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
115–227（113 aa）
|
Not recorded | SO4 SULFATE ION × 6 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.4 M ammonium sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.230 |
| 5VZX Crystal structure of crenezumab Fab Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
115–227（113 aa）
|
Not recorded | SO4 SULFATE ION × 5 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；2.4 M ammonium sulfate, 0.1M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.230 |
| 5VZY Crystal structure of crenezumab Fab in complex with Abeta Deposited 2017-05-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
115–227（113 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M magnesium chloride hexahydrate, 0.1 M Tris hydrochloride pH 8.5, 30% w/v polyethylene glycol 4000
|
Resolution 2.32 Å R-free 0.249 |
| 5W5L Crystal structure of human IgG1-Sigma Fc fragment Deposited 2017-06-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
227–449（223 aa）
Fragment：Sigma Fc fragment, UNP residues 227-449
Chain B
227–449（223 aa）
Fragment：Sigma Fc fragment, UNP residues 227-449
|
Mutation：L234A, L235A, A237G, P238S, H268A, A330S, P331S Mutation：L234A, L235A, A237G, P238S, H268A, A330S, P331S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；9% PEG 20,000, 0.1 M Sodium Acetate, pH 5.5
|
Resolution 1.90 Å R-free 0.229 |
| 5WAV Fc AbVance: Increasing our knowledge of antibody structural space to enable faster and better decision-making in antibody drug discovery. Deposited 2017-06-27 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
240–448（209 aa）
Chain B
240–448（209 aa）
|
Not recorded | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；0.1M Hepes pH7.5
10% v/v polyethylene glycol 8000
8% v/v ethylene glycol
|
Resolution 2.60 Å R-free 0.260 |
| 5XJE Crystal structure of fucosylated IgG1 Fc complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa Deposited 2017-05-01 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
Chain B
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；12% PEG 20000, 0.1 M MES (pH 6.5), 4% Zwittergent 3-12
|
Resolution 2.40 Å R-free 0.281 |
| 5XJF Crystal structure of fucosylated IgG Fc Y296W mutant complexed with bis-glycosylated soluble form of Fc gamma receptor IIIa Deposited 2017-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
Chain B
227–449（223 aa）
Fragment：UNP RESIDUES 227-449
|
Mutation：Y298W Mutation：Y298W | CL CHLORIDE ION × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；12% PEG 20000, 0.1 M MES (pH 6.5), 4% Zwittergent 3-14
|
Resolution 2.50 Å R-free 0.270 |
| 5XMH Crystal structure of an IgM rheumatoid factor YES8c in complex with IgG1 Fc Deposited 2017-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
239–446（208 aa）
Fragment：UNP RESIDUES 239-446
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Tris-HCl, sodium acetate, PEG 4000
|
Resolution 2.80 Å R-free 0.272 |
| 5XMH Crystal structure of an IgM rheumatoid factor YES8c in complex with IgG1 Fc Deposited 2017-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
239–446（208 aa）
Fragment：UNP RESIDUES 239-446
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Tris-HCl, sodium acetate, PEG 4000
|
Resolution 2.80 Å R-free 0.272 |
| 5Y56 Fc mutant (K392D/K409D/D399K) Deposited 2017-08-07 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–445（208 aa）
Fragment：UNP residues 238-445
Chain B
238–445（208 aa）
Fragment：UNP residues 238-445
|
Mutation：K392D/K409D/D399K Mutation：K392D/K409D/D399K | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1.5M (NH4)2SO4, 10% Glycerol, 0.1M Tris-Hcl (pH 7.5)
|
Resolution 2.65 Å R-free 0.298 |
| 5YC5 Crystal structure of human IgG-Fc in complex with aglycan and optimized Fc gamma receptor IIIa Deposited 2017-09-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
226–448（223 aa）
Fragment：Fc fragment, UNP residues 226-448
Chain B
226–448（223 aa）
Fragment：Fc fragment, UNP residues 226-448
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293.15 K；20mM Tris-HCl, 100mM NaCl, 14% PEG 3350
|
Resolution 2.71 Å R-free 0.273 |
| 6APD Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425 Deposited 2017-08-17 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 15 PDB declaration: pentadecameric |
Chain J
109–223（115 aa）
Chain K
109–223（115 aa）
Chain N
109–223（115 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；10% PEG 4000
10% 2-propanol
0.1 M sodium citrate pH 5.5
|
Resolution 4.10 Å R-free 0.256 |
| 6ARP Structure of a mutant Cetuximab Fab fragment Deposited 2017-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
120–222（103 aa）
|
Not recorded | SO4 SULFATE ION × 3 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol
|
Resolution 1.70 Å R-free 0.197 |
| 6ARP Structure of a mutant Cetuximab Fab fragment Deposited 2017-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
120–222（103 aa）
|
Not recorded | SO4 SULFATE ION × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol
|
Resolution 1.70 Å R-free 0.197 |
| 6ARU Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain Deposited 2017-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
120–222（103 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；150 mM ammonium sulfate, 16.5% PEG3350, 10 mM cadmium chloride, 100 mM imidazole, 5% glycerol
|
Resolution 3.20 Å R-free 0.267 |
| 6B70 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain and insulin Deposited 2017-10-03 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton and homemade plunger
|
Resolution 3.70 Å |
| 6B7Z Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11 heavy chain and FAB H11 light chain Deposited 2017-10-05 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton
|
Resolution 6.50 Å |
| 6BF7 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain Deposited 2017-10-26 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton
|
Resolution 6.50 Å |
| 6BF9 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain Deposited 2017-10-26 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
125–219（95 aa）
Chain E
125–219（95 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton
|
Resolution 7.20 Å |
| 6BFT Structure of Bevacizumab Fab mutant in complex with VEGF Deposited 2017-10-27 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
120–227（108 aa）
Chain H
120–227（108 aa）
|
Not recorded | SO4 SULFATE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；100 mM MES, 6.0, 225 mM ammonium sulfate, 13% PEG4000, 10% isopropanol
|
Resolution 2.55 Å R-free 0.220 |
| 6BGT Structure of Trastuzumab Fab mutant in complex with Her2 extracellular domain Deposited 2017-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；293 K；100 mM MES, pH 6.5, 18% PEG3350, 10% glycerol
|
Resolution 2.70 Å R-free 0.247 |
| 6BKB Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3A Deposited 2017-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.2；293 K；20% (w/v) PEG 3500, 0.2M sodium-citrate
|
Resolution 2.80 Å R-free 0.267 |
| 6BKC Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3B Deposited 2017-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.7；293 K；20% (w/v) PEG 3500, 0.2M Li-chloride
|
Resolution 2.60 Å R-free 0.276 |
| 6BZ4 Human IgG1 lacking complement-dependent cytotoxicity: hu3S193 Fc mutant K322A Deposited 2017-12-22 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Chain B
239–446（208 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；PEG 6000, 0.1 M MES, 25% V/V ETHYLENE GLYCOL
|
Resolution 2.40 Å R-free 0.249 |
| 6DKJ human GIPR ECD and Fab complex Deposited 2018-05-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–222（114 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10% PEG 4000 and 20% isopropanol
|
Resolution 1.95 Å R-free 0.238 |
| 6DKJ human GIPR ECD and Fab complex Deposited 2018-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
109–222（114 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10% PEG 4000 and 20% isopropanol
|
Resolution 1.95 Å R-free 0.238 |
| 6EAQ Glycosylated FCGR3B / CD16b in complex with afucosylated IgG1 Fc Deposited 2018-08-03 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–446（220 aa）
Chain B
227–446（220 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；pH 6.0 50 mM MES, 8% PEG3350 and 60 mM NaCl
|
Resolution 2.22 Å R-free 0.244 |
| 6FCZ Model of gC1q-Fc complex based on 7A EM map Deposited 2017-12-21 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain H
234–449（216 aa）
Fragment：UNP residues 234-449
Chain K
234–449（216 aa）
Fragment：UNP residues 234-449
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 10.00 Å |
| 6FGO Fc in complex with engineered calcium binding domain Z Deposited 2018-01-11 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
239–448（210 aa）
Chain C
239–448（210 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 5 GOL GLYCEROL × 7 CA CALCIUM ION × 2 CL CHLORIDE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；24 % PEG3350, 0.1 M LiCl2, 0.1 M MES pH 6.0
|
Resolution 2.50 Å R-free 0.232 |
| 6FGO Fc in complex with engineered calcium binding domain Z Deposited 2018-01-11 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
239–448（210 aa）
Chain D
239–448（210 aa）
|
Not recorded | GOL GLYCEROL × 8 CA CALCIUM ION × 2 CL CHLORIDE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；24 % PEG3350, 0.1 M LiCl2, 0.1 M MES pH 6.0
|
Resolution 2.50 Å R-free 0.232 |
| 6G1E BEAT Fc with improved heterodimerization (Q3A-D84.4Q) Deposited 2018-03-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
223–449（227 aa）
|
Mutation：L234A, L235A, Q347E, Y349A, L351F, S364T, T366V, K370T, T394D, V397L, D399E, D401Q, F405A, Y407S, K409R, T411R Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；CRYSTALS GROWN BY VAPOR DIFFUSION BY MIXING 12.0 MG/ML PROTEIN IN 10 MM HEPES PH8.0, 100 MM NACL, 1 MM EDTA, EQUALLY WITH 33.00 %(W/V) PEG 1500
|
Resolution 1.88 Å R-free 0.272 |
| 6IFJ Structure of bispecific Fc Deposited 2018-09-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Mutation：E357K,K409R Mutation：K370E | GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291.15 K；0.1M Hepes, pH7.5, 12%(w/v) polyethylene glycol 3350
|
Resolution 2.40 Å R-free 0.231 |
| 6IQG X-ray crystal structure of Fc and peptide complex Deposited 2018-11-08 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
238–447（210 aa）
Chain B
238–447（210 aa）
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.9；293 K；PEG 3350, KI
|
Resolution 3.00 Å R-free 0.273 |
| 6IQH X-ray crystal structure of covalent-bonded complex of Fc and peptide Deposited 2018-11-08 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
238–447（210 aa）
Chain B
238–447（210 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10；293 K；0.1 M CHES pH 10.0, 0.3M NaCl, 20% (w/v) PEG 8000
|
Resolution 3.00 Å R-free 0.293 |
| 6KA7 The complex structure of Human IgG Fc and its binding Repebody Deposited 2019-06-21 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
240–447（208 aa）
Chain D
240–447（208 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Tris HCl, PEG 4000, Sodium chloride
|
Resolution 3.00 Å R-free 0.333 |
| 6MB3 Cryo-EM structure of the circumsporozoite protein of Plasmodium falciparum with a vaccine-elicited antibody reveals maturation of inter-antibody contacts Deposited 2018-08-29 | Different construct Different mutation/modification Different oligomeric state Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 19 PDB declaration: nonadecameric |
Chain A
109–223（115 aa）
Chain B
109–223（115 aa）
Chain C
109–223（115 aa）
Chain D
109–223（115 aa）
Chain F
109–223（115 aa）
Chain G
109–223（115 aa）
Chain H
109–223（115 aa）
Chain I
109–223（115 aa）
Chain J
109–223（115 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.37 Å |
| 6MSY Anti-HIV-1 Fab Fab 2G12 + Man4 re-refinement Deposited 2018-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–221（102 aa）
|
Not recorded | UNX UNKNOWN LIGAND × 8 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；295 K；27% Peg 4000, 0.05M sodium acetate
|
Resolution 2.00 Å R-free 0.242 |
| 6MU3 Anti-HIV-1 Fab 2G12 + Man7 re-refinement Deposited 2018-10-22 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–221（102 aa）
Chain M
120–221（102 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；295 K；20% Peg 4000, 0.2M sodium tartrate
|
Resolution 2.33 Å R-free 0.234 |
| 6MUB Anti-HIV-1 Fab 2G12 + Man5 re-refinement Deposited 2018-10-22 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–222（103 aa）
Chain M
120–222（103 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；295 K；1.6M sodium/potassium phosphate
|
Resolution 2.50 Å R-free 0.280 |
| 6N2X Anti-HIV-1 Fab 2G12 + Man9 re-refinement Deposited 2018-11-14 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–220（101 aa）
Chain M
120–220（101 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；25% Peg 400, 0.2M imidazole malate
|
Resolution 3.00 Å R-free 0.283 |
| 6N32 Anti-HIV-1 Fab 2G12 re-refinement Deposited 2018-11-14 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–221（102 aa）
Chain K
120–221（102 aa）
|
Not recorded | SO4 SULFATE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；298 K；1.05M ammonium sulfate, 18% Peg 6000, 0.1M imidazole malate
|
Resolution 2.20 Å R-free 0.227 |
| 6N35 Anti-HIV-1 Fab 2G12 + Man1-2 re-refinement Deposited 2018-11-14 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain H
120–220（101 aa）
Chain M
120–220（101 aa）
|
Not recorded | BEZ BENZOIC ACID × 1 GOL GLYCEROL × 1 MAN alpha-D-mannopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2M Sodium/Potassium Phosphate
|
Resolution 1.75 Å R-free 0.238 |
| 6OGE Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex Deposited 2019-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
109–222（114 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.36 Å |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
109–226（118 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
109–226（118 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain F
109–226（118 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6UBI N123-VRC34.05 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 Deposited 2019-09-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
117–226（110 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES, pH 7, 30% PEG6000
|
Resolution 1.90 Å R-free 0.288 |
| 6UBI N123-VRC34.05 HIV neutralizing antibody in complex with HIV fusion peptide residue 512-519 Deposited 2019-09-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
117–226（110 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M HEPES, pH 7, 30% PEG6000
|
Resolution 1.90 Å R-free 0.288 |
| 6UGW Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a C-centered orthorhombic crystal form, Lot A Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
220–449（230 aa）
Fragment：LotA_Fc
|
Not recorded | ZN ZINC ION × 6 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；10 mg/mL protein with JCSG+ E7 (266849e7): 10% 2-propanol, 200 mM zinc acetate, 100 mM sodium cacodylate, pH 6.5, cryoprotectant: 20% ethylene glycol, puckID kux1-2
|
Resolution 2.00 Å R-free 0.219 |
| 6UGX Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a primative orthorhombic crystal form, Lot A Deposited 2019-09-26 | Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
220–449（230 aa）
Chain B
220–449（230 aa）
|
Not recorded | K POTASSIUM ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；10 mg/mL protein with 200 mM potassium nitrate, 20% PEG3350, cryoprotectant: 20% ethylene glycol, puckID sxt1-6
|
Resolution 2.10 Å R-free 0.256 |
| 6UGY Crystal structure of the Fc fragment of anti-TNFa antibody infliximab (Remicade) in a primative orthorhombic crystal form, Lot C Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
220–449（230 aa）
Fragment：LotC_Fc
|
Not recorded | ZN ZINC ION × 6 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；10 mg/mL protein with JCSG+ E7 Opt screen H2 (267146h2): 4% 2-propanol, 200 mM zinc acetate, 100 mM sodium cacodylate, pH 6.8, cryoprotectant: 20% ethylene glycol, puckID kux1-9
|
Resolution 2.10 Å R-free 0.228 |
| 6UOE 3-25 Fab germline-reversion variant bound to an HCMV gB-derived peptide Deposited 2019-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
109–223（115 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1 M magnesium chloride, 13.4% PEG3350, 16.75% PEG400, 0.1 M Tris, pH 8.5
|
Resolution 1.80 Å R-free 0.186 |
| 6V8Z VRC03 and 10-1074 Bound BG505 F14 HIV-1 SOSIP Envelope Trimer Structure Deposited 2019-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 18 PDB declaration: octadecameric |
Chain C
117–220（104 aa）
Chain I
117–220（104 aa）
Chain O
117–220（104 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 21 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å |
| 6VSL Crystal structure of a human fucosylated IgG1 Fc expressed in tobacco plants (Nicotiana benthamiana) Deposited 2020-02-11 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
Chain B
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
|
Not recorded | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；15% PEG4000, 0.1 M HEPES, pH 7.0
|
Resolution 2.10 Å R-free 0.250 |
| 6VSZ Crystal structure of a human afucosylated IgG1 Fc expressed in tobacco plants (Nicotiana benthamiana) Deposited 2020-02-12 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
Chain B
236–446（211 aa）
Fragment：crystallizable fragment (UNP residues 236-446)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；15% PEG4000, 0.1 M HEPES, pH 7.0
|
Resolution 2.60 Å R-free 0.276 |
| 6X3I NNAS Fc mutant Deposited 2020-05-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
227–449（223 aa）
Fragment：Fc
|
Not recorded | BMA beta-D-mannopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；30% polyethylene glycol 1500
|
Resolution 2.27 Å R-free 0.221 |
| 6YSC GLYCOSYLATED KNOB-HOLE/DUMMY FC FRAGMENT Deposited 2020-04-22 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–449（227 aa）
Chain B
223–449（227 aa）
|
Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；294 K；15% (w/v) PEG4000, 0.1M HEPES
|
Resolution 2.05 Å R-free 0.293 |
| 6YT7 GLYCOSYLATED KNOB/DUMMY-HOLE FC FRAGMENT Deposited 2020-04-24 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–449（227 aa）
|
Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；294 K；25% (w/v) PEG2000 MME, 0.1M HEPES
|
Resolution 1.55 Å R-free 0.273 |
| 6YTB GLYCOSYLATED KNOB/DUMMY-HOLE/DUMMY FC FRAGMENT Deposited 2020-04-24 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–449（227 aa）
Chain B
223–449（227 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；294 K；20% (w/v) PEG3350, 0.2M potassium formate
|
Resolution 1.65 Å R-free 0.249 |
| 7CZQ S protein of SARS-CoV-2 in complex bound with P2B-1A10 Deposited 2020-09-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 7 PDB declaration: heptameric |
Chain H
115–449（335 aa）
Chain J
115–449（335 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 7CZT S protein of SARS-CoV-2 in complex bound with P5A-2G9 Deposited 2020-09-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 7 PDB declaration: heptameric |
Chain H
109–449（341 aa）
Chain I
109–449（341 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å |
| 7CZU S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B Deposited 2020-09-09 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 7 PDB declaration: heptameric |
Chain H
109–449（341 aa）
Chain J
109–449（341 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7CZV S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 9 PDB declaration: nonameric |
Chain H
109–449（341 aa）
Chain I
109–449（341 aa）
Chain J
109–449（341 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 31 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 540 PDB declaration: 540-meric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 9 PDB declaration: nonameric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 45 PDB declaration: 45-meric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 54 PDB declaration: 54-meric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7T17 Zika Virus asymmetric unit bound with IgM antibody DH1017 Fab fragment Deposited 2021-12-01 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 9 PDB declaration: nonameric |
Chain H
120–224（105 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.26 Å |
| 7URU Crystal structure of the low affinity Fc gamma receptor IIIA variant in complex with the Fc of IgG1. Deposited 2022-04-22 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；294 K；8% PEG 8000
0.1 M HEPES pH 7.0
|
Resolution 2.40 Å R-free 0.262 |
| 7X13 Structure of IgG-Fc hexamer Deposited 2022-02-23 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
223–443（221 aa）
Chain B
223–443（221 aa）
Chain C
223–443（221 aa）
Chain D
223–443（221 aa）
Chain E
223–443（221 aa）
Chain F
223–443（221 aa）
Chain G
223–443（221 aa）
Chain H
223–443（221 aa）
Chain I
223–443（221 aa）
Chain J
223–443（221 aa）
Chain K
223–443（221 aa）
Chain L
223–443（221 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å |
| 8DAO Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV44-79 Deposited 2022-06-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain E
120–222（103 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M Tris, pH 8.5, 0.01 M nickel (II) chloride, and 20% PEG monomethyl ether 2000
|
Resolution 2.80 Å R-free 0.284 |
| 8DAO Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV44-79 Deposited 2022-06-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain G
120–222（103 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1 M Tris, pH 8.5, 0.01 M nickel (II) chloride, and 20% PEG monomethyl ether 2000
|
Resolution 2.80 Å R-free 0.284 |
| 8DBZ CryoEM structure of Hantavirus ANDV Gn(H) protein complex with 2Fabs ANDV-5 and ANDV-34 Deposited 2022-06-15 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 9 PDB declaration: nonameric |
Chain F
120–222（103 aa）
Fragment：UNP residues 120-222
Chain H
120–222（103 aa）
Fragment：UNP residues 120-222
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.10 Å |
| 8DV1 SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to linker variant of affinity matured ACE2 mimetic CVD432 Deposited 2022-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
218–449（232 aa）
|
Mutation：K31F,N33D,H34S,E35Q | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 8DV2 SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to computationally engineered ACE2 mimetic CVD293 Deposited 2022-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
218–449（232 aa）
|
Mutation：K31F,H34I,E35Q | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å |
| 8ECQ Bovine Fab 2G3 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
115–222（108 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 3 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；277.15 K；10% glycerol, 0.1M Mes, 5% Peg1000, 30% Peg600
|
Resolution 2.00 Å R-free 0.253 |
| 8ECV Bovine Fab 2F12 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
114–222（109 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293.15 K；0.2M sodium chloride, 0.1M phosphate-citrate buffer, 20% Peg6000
|
Resolution 1.81 Å R-free 0.261 |
| 8ECV Bovine Fab 2F12 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
114–222（109 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293.15 K；0.2M sodium chloride, 0.1M phosphate-citrate buffer, 20% Peg6000
|
Resolution 1.81 Å R-free 0.261 |
| 8ECZ Bovine Fab 4C1 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
114–222（109 aa）
|
Not recorded | PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1M Tris, 50% MPD, 0.2M ammonium dihydrogen phosphate
|
Resolution 2.82 Å R-free 0.258 |
| 8ECZ Bovine Fab 4C1 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
114–222（109 aa）
|
Not recorded | PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293.15 K；0.1M Tris, 50% MPD, 0.2M ammonium dihydrogen phosphate
|
Resolution 2.82 Å R-free 0.258 |
| 8ED1 Bovine Fab 5C1 Deposited 2022-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain H
114–222（109 aa）
|
Not recorded | GOL GLYCEROL × 3 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277.15 K；0.1M Tris, 10% glycerol, 20% Peg300, 5% Peg8000
|
Resolution 2.31 Å R-free 0.267 |
| 8EDF Bovine Fab SKD in complex with Sars COV-2 receptor binding domain Deposited 2022-09-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain H
114–222（109 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.2；293.15 K；0.4M Lithium chloride, 10% Peg6000, 0.1M sodium citrate
|
Resolution 3.40 Å R-free 0.299 |
| 8GHR Structure of human ENPP1 in complex with variable heavy domain VH27.2 Deposited 2023-03-10 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Not recorded | ZN ZINC ION × 4 AMP ADENOSINE MONOPHOSPHATE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 CA CALCIUM ION × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；phosphate buffered saline
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å |
| 8TTM IgG1 Fc Heterodimer combYSelect1 Deposited 2023-08-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Mutation：K409S, T411Y Mutation：L368S, D399Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；292 K；0.1M BisTris pH 6.5 and 21% PEG MME 5000
|
Resolution 2.51 Å R-free 0.242 |
| 8TUD IgG1 Fc Heterodimer combYSelect2 Deposited 2023-08-16 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
218–449（232 aa）
Chain B
218–449（232 aa）
|
Mutation：D399Y, K447S Mutation：K409S, T411Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；292 K；0.1M Bis Tris pH 6.5 and 29% PEG MME 2000
|
Resolution 3.00 Å R-free 0.285 |
| 8URO Crystal structure of IgG1-Fc fragment (E382S) in complex with Corynebacterial ENGase CU43 (D187A-E189A) Deposited 2023-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
218–449（232 aa）
Chain C
218–449（232 aa）
|
Mutation：E382S Mutation：E382S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium acetate 0.1 M MES 6.5 30 %v/v Glycerol ethoxylate (MIDAS 2-31)
|
Resolution 3.62 Å R-free 0.369 |
| 8URO Crystal structure of IgG1-Fc fragment (E382S) in complex with Corynebacterial ENGase CU43 (D187A-E189A) Deposited 2023-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain E
218–449（232 aa）
Chain F
218–449（232 aa）
|
Mutation：E382S Mutation：E382S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M Ammonium acetate 0.1 M MES 6.5 30 %v/v Glycerol ethoxylate (MIDAS 2-31)
|
Resolution 3.62 Å R-free 0.369 |
| 8W4L Crystal structure of closed conformation of human immunoglobulin Fc in presence of EndoSz Deposited 2023-08-24 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100 mM MES PH 6.0
200 mM Zinc acetate
10 % PEG 8000
|
Resolution 3.10 Å R-free 0.257 |
| 8W4M Crystal structure of open conformation of human immunoglobulin Fc in presence of EndoSz Deposited 2023-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
227–449（223 aa）
|
Not recorded | ZN ZINC ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；100 mM MES PH 6.5
200 mM Zinc acetate
10 % PEG 8000
|
Resolution 2.18 Å R-free 0.255 |
| 8ZCK Serial Femtosecond Crystallography Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-04-30 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.00 Å R-free 0.227 |
| 8ZCL Ambient Temperature Crystal Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-04-30 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.60 Å R-free 0.236 |
| 8ZCM Cryogenic Temperature Crystal Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-04-30 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 2.64 Å R-free 0.409 |
| 9BEX X-ray crystallography structural model of the immunoglobulin G1 (IgG1) Fc D270C K326C variant Deposited 2024-04-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain AAA
218–449（232 aa）
Chain BBB
218–449（232 aa）
|
Mutation：D270C,K326C Mutation：D270C,K326C | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1M HEPES pH 7.5, 10% PEG 3350
|
Resolution 2.25 Å R-free 0.302 |
| 9CRT Crystal structure of IgG1 FC at natural pH Deposited 2024-07-22 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；0.1 M Hepes pH 7.5 and 20% PEG 20,000
|
Resolution 2.19 Å R-free 0.282 |
| 9CXL Crystal structure of IgG1 FC WT at pH 5.5 Deposited 2024-07-31 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；1 M Ammonium sulfate, 0.1 M Sodium citrate pH 5.5
|
Resolution 2.33 Å R-free 0.279 |
| 9CY6 Crystal structure of IgG1 FC M252H at pH 7.5 Deposited 2024-08-01 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252H Mutation：M252H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1 M Bis-tris propane pH 7.5, and 8% PEG8K
|
Resolution 2.06 Å R-free 0.282 |
| 9D06 Crystal structure of IgG1 FC M252R at pH 5.6 Deposited 2024-08-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252R Mutation：M252R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；0.1M Sodium citrate pH 5.6, 20% Propanol and 20% PEG 4K
|
Resolution 2.33 Å R-free 0.279 |
| 9D09 Crystal structure of IgG1 FC M252H at pH 5.6 Deposited 2024-08-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252H Mutation：M252H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；0.1M Sodium citrate pH 5.6, 20% Propanol and 20% PEG 4000
|
Resolution 2.92 Å R-free 0.283 |
| 9D9Q Crystal structure of IgG1 FC M252R at pH 8.0 Deposited 2024-08-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
238–449（212 aa）
Chain B
238–449（212 aa）
|
Mutation：M252R Mutation：M252R | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295 K；0.1 M Tris pH 8.0 and 0.08M Sodium formate and 7.5% PEG20K
|
Resolution 2.82 Å R-free 0.367 |
| 9DAZ Molecular basis of pathogenicity of the recently emerged FCoV-23 coronavirus. Complex of fAPN with FCoV-23 RBD Deposited 2024-08-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
218–449（232 aa）
Chain C
218–449（232 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 ZN ZINC ION × 2 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.50 Å |
| 9IIE Cryogenic Temperature Crystal Structure of Fc Fragment of Human IgG1 from Biosimilar VEGF-Trap Deposited 2024-06-20 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
239–446（208 aa）
Fragment：Fc Fragment
Chain B
239–446（208 aa）
Fragment：Fc Fragment
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1M Bis-Tris pH 6.5, 25% w/v Polyethylene glycol 3350
|
Resolution 3.14 Å R-free 0.309 |
| 9K2Y Human IgG1 Fc fragments, mutant (2CT1.1) Deposited 2024-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
Chain C
227–449（223 aa）
Chain D
227–449（223 aa）
|
Not recorded | GAL beta-D-galactopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；50mM Sodium phosphate pH 7.0, 16% PEG 3350
|
Resolution 3.12 Å R-free 0.281 |
| 9K34 Human IgG1 Fc fragments, mutant (2CT1.9) Deposited 2024-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
Chain C
227–449（223 aa）
Chain D
227–449（223 aa）
|
Not recorded | FUL beta-L-fucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；50mM HEPES pH 7.0, 10% PEG 3350
|
Resolution 3.00 Å R-free 0.279 |
| 9LOC Cryo-EM structure of human FcRL5 bound to IgG-Fc Deposited 2025-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 13 PDB declaration: 13-meric |
Chain B
218–443（226 aa）
Chain C
218–443（226 aa）
Chain D
218–443（226 aa）
Chain E
218–443（226 aa）
Chain F
218–443（226 aa）
Chain G
218–443（226 aa）
Chain H
218–443（226 aa）
Chain I
218–443（226 aa）
Chain J
218–443（226 aa）
Chain K
218–443（226 aa）
Chain L
218–443（226 aa）
Chain M
218–443（226 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 13 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.56 Å |
| 9LOD Local structure of human FcRL5 bound to IgG-Fc Deposited 2025-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain B
218–443（226 aa）
Chain C
218–443（226 aa）
Chain D
218–443（226 aa）
Chain E
218–443（226 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.16 Å |
| 9MCX CRYSTAL STRUCTURE OF HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR IIA COMPLEX H131 VARIANT Deposited 2024-12-05 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；25% PEG 2000 MME, 0.1 M HEPES pH 7.5
|
Resolution 2.38 Å R-free 0.234 |
| 9MCY CRYSTAL STRUCTURE OF HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR IIA COMPLEX R131 VARIANT Deposited 2024-12-05 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；10% PEG 5000 MME, 12% isopropanol , 0.1 M MES pH 6.5
|
Resolution 2.85 Å R-free 0.236 |
| 9MCY CRYSTAL STRUCTURE OF HUMAN IGG1 FC FRAGMENT-FC-GAMMA RECEPTOR IIA COMPLEX R131 VARIANT Deposited 2024-12-05 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
227–449（223 aa）
Chain D
227–449（223 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；294 K；10% PEG 5000 MME, 12% isopropanol , 0.1 M MES pH 6.5
|
Resolution 2.85 Å R-free 0.236 |
| 9OUV Crystal structure of human IGG1 FC fragment-FC-gamma receptor IIB complex Deposited 2025-05-29 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
227–449（223 aa）
Chain B
227–449（223 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；150 mM sodium chloride
100 mM Tris-HCl pH 8.0
8% PEG 6000
|
Resolution 3.07 Å R-free 0.241 |
| 9UO5 Cryo-EM structure of the human IgG-Fc hexamer Deposited 2025-04-25 | Different construct Different mutation/modification Different oligomeric state Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
218–443（226 aa）
Chain B
218–443（226 aa）
Chain C
218–443（226 aa）
Chain D
218–443（226 aa）
Chain E
218–443（226 aa）
Chain F
218–443（226 aa）
Chain G
218–443（226 aa）
Chain H
218–443（226 aa）
Chain I
218–443（226 aa）
Chain J
218–443（226 aa）
Chain K
218–443（226 aa）
Chain L
218–443（226 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.75 Å |
| 9UOK Structure of the complex of LGR4_ECD with Norrin Deposited 2025-04-25 | Different oligomeric state Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
220–449（230 aa）
Chain F
220–449（230 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.05 Å |
105 other PDB entries and 128 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | IGG1_HUMAN |
| Isoform | — |
| PDB entities | 2 |
| Chains and sequence ranges | Author chain E； PDBConstruct 172–401； UniProt 220–449 Author chain F； PDBConstruct 172–401； UniProt 220–449 |
